SCHEMBL4095719

SCHEMBL4095719

O=C(O)CCN1C(=O)c2ccc(C(NC(=O)Nc3ccc(OC(F)(F)F)cc3)c3ccc4nc(S)sc4c3)cc2C1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
KDM4E B2RXH2 5/20 0.39
HPGD P15428 6/20 0.39
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 4/20 0.39
RECQL P46063 1/20 0.38
NPC1 O15118 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
DYRK1A Q13627 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7080574 0.85 CASR (0.38) DYRK1AHDAC3HDAC4HDAC1HDAC7
SCHEMBL4081252 0.81 GCGR (0.49)
SCHEMBL4095710 0.80 GCGR (0.43) MAPTKDM4EHPGDALDH1A1HSD17B10
SCHEMBL7161888 0.72 EPHX2 (0.49) HDAC8
SCHEMBL4086528 0.66 ALDH1A1 (0.41) KDM4EHPGDALDH1A1HSD17B10NPC1
SCHEMBL7080572 0.66 GCGR (0.44) CASRCSNK1D
SCHEMBL4081246 0.63 GCGR (0.67)
SCHEMBL2749943 0.63 NPC1 (0.68) HSD17B10NPC1NFKB1RAB9ASMN1; SMN2
SCHEMBL13197506 0.63 DYRK1A (0.45) MAPTHSD17B10NPC1NFKB1RAB9A
SCHEMBL13204823 0.62 DYRK1A (0.44) MAPTALDH1A1HSD17B10NPC1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR MAPT 4379/4885KDM4E 3664/4885HPGD 1678/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR MAPT 4379/4885KDM4E 3664/4885HPGD 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.